Compare OPTT & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | ALZN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.5M |
| IPO Year | 2006 | 2021 |
| Metric | OPTT | ALZN |
|---|---|---|
| Price | $0.43 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 606.2K | 28.6K |
| Earning Date | 12-14-2026 | 12-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,737,000.00 | N/A |
| Revenue This Year | $286.98 | N/A |
| Revenue Next Year | $131.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.84 |
| 52 Week High | $3.23 | $2.56 |
| Indicator | OPTT | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 53.40 |
| Support Level | $0.40 | $1.41 |
| Resistance Level | $0.52 | $2.20 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 20.65 | 58.04 |
Ocean Power Technologies Inc is specializing in intelligent maritime solutions. These solutions include a variety of as a service systems, including Data as a Service (DaaS), Robotics as a Service (RaaS), and Power as a Service (PaaS). It design, manufacture, deploy, and operate these systems for defense, security, subsea infrastructure, offshore oil and gas, offshore energy, marine research, and communication markets. The company operates as one operating segment. Majority of revenue comes from Europe followed by North & South America; and followed by Asia and Australia.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.